Previous 10 | Next 10 |
2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...
Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Conference Call March 02, 2023 08:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer ...
Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q4 GAAP EPS of -$0.17 beats by $1.13 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $202.3 million, as compared with $143.4 million on December 31, 2021. Based on its current plans, Syro...
-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment in SELECT-MDS-1 trial in 4Q 2023, with pivotal data expecte...
Gainers: Okta ( OKTA ) +13% . Kezar Life Sciences ( KZR ) +7% . Esperion Therapeutics. ( ESPR ) +6% . Syros Pharmaceuticals ( SYRS ) +5% . ImmunityBio ( IBRX ) +5% . Losers: Funko ( FNKO ) -27% . ZimVie ( ZIMV ...
Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$1.36 (-257.9% Y/Y) and the consensus Revenue Estimate is $3.85M (-95.1% Y/Y). Over the last 2 years, SYRS has beate...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its four...
Summary Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% o...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Syros Pharmaceuticals' ( NASDAQ: SYRS ) tamibarotene to treat higher-risk myelodysplastic syndrome (HR-MDS). MDS are a group of cancers in which immature blood cells in the bone marrow do not mature or becom...
-- Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new ...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...